within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB04_Glibornuride;

model Glibornuride
  extends Pharmacolibrary.Drugs.ATC.A.A10BB04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BB04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Glibornuride is an oral sulfonylurea antidiabetic agent used for the treatment of type 2 diabetes mellitus by stimulating insulin secretion from pancreatic beta cells. It has been withdrawn or is rarely used today due to the availability of newer agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for typical adult population due to absence of specific published human PK models. Parameters are estimated from available product characteristics and reference-class data.</p><h4>References</h4><ol><li><p>Rentsch, G, et al., &amp; Rieder, J (1972). [Pharmacokinetics of glibornuride]. <i>Arzneimittel-Forschung</i> 22 2209–None. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4679250/\">https://pubmed.ncbi.nlm.nih.gov/4679250</a></p></li><li><p>Dubach, UC, et al., &amp; Raaflaub, J (1975). [On the multiple-dose kinetics of glibornuride in man (author&#x27;s transl)]. <i>Arzneimittel-Forschung</i> 25(12) 1967–1969. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/130138/\">https://pubmed.ncbi.nlm.nih.gov/130138</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Glibornuride;
